What is the difference between the drug Liprimar and Atorvastatin and which one is better?

Prohibited during pregnancy

Prohibited during breastfeeding

Has restrictions for children

Allowed for older people

Has limitations for liver problems

Allowed for kidney problems

Cholesterol (CS) is a fat-like alcohol that performs many important functions in the human body. With its help, bile acids are produced, the stability and elasticity of cell membranes, the synthesis of steroidal and non-steroidal hormones, as well as vitamins D, A and E. Cholesterol is very beneficial for the body, but only if it does not exceed normal levels.

An increased cholesterol index in the blood leads to the development of systemic and cardiac diseases, and is also the main factor in the formation of atherosclerotic deposits inside the arterial membranes.

To lower your cholesterol index, you need to switch to a low-cholesterol diet, give up bad habits (alcohol and nicotine) and increase activity.

But non-drug control methods are not always effective; then, to reduce cholesterol, drugs from the statin group are prescribed, most often based on the active component atorvastatin. In this article we will figure out what is better to take for high cholesterol - Atorvastatin or Liprimar.

Liprimar - instructions for use (Method and dosage)

According to the instructions for use of Liprimar, these tablets are intended for oral administration.
When starting treatment with atorvastatin, the level of cholesterol in the blood is first determined, and then diet and exercise are prescribed. Liprimar is usually recommended when other non-drug methods become ineffective. Taking these tablets does not depend on food intake or time of day. In this case, the daily dose assumes a single dose. After 2-4 weeks, dosage adjustment is possible, at the discretion of the attending physician. The development of the therapeutic effect is noted after 2 weeks. The maximum concentration is reached within a month from the start of administration.

Treatment with Liprimar can increase the activity of liver enzymes, so regular monitoring of liver functions is required during this period.

Comparison of addiction between Atoris and Liprimar

Like safety, addiction also involves many factors that must be considered when evaluating a drug.

So, the totality of the values ​​of such parameters as “o syndrome” in Atoris is quite similar to the similar values ​​in Liprimar. Withdrawal syndrome is a pathological condition that occurs after the cessation of intake of addictive or dependent substances into the body. And resistance is understood as initial immunity to a drug; in this it differs from addiction, when immunity to a drug develops over a certain period of time. The presence of resistance can only be stated if an attempt has been made to increase the dose of the drug to the maximum possible. At the same time, at Atoris the meaning of the “syndrome” is quite small, however, the same as for Liprimar.

What to choose

Which manufacturer of Atorvastatin is better
? The drugs belong to the same group. They can be prescribed by a doctor in any dosage, but always start with the smallest doses, gradually increasing if necessary. Provided Roxer is available in the pharmacy and its cost is affordable for people, doctors more often prescribe it, since it is noted that fewer side effects occur after taking it.

High cholesterol at the present stage of development of society is one of the most common problems among the older generation. In recent years, the presence of high cholesterol has been increasingly recorded among the younger generation.

The reasons for the rejuvenation of pathology are the frequent occurrence of stressful psychological stress on the body, a violation of the nutritional culture, eating a large amount of potentially dangerous foods, as well as leading a sedentary lifestyle. All of these factors provoke metabolic disorders in the body.

To eliminate the emerging pathological condition, it is necessary to select a good and effective medication for therapeutic correction of cholesterol levels in the blood plasma.

To reduce high cholesterol levels in the body, doctors most often recommend the use of medications belonging to the group of statins.

Two drugs in this group are especially popular - Crestor or Roxera.

These lipid-lowering drugs are produced by the manufacturer in the form of tablets for oral administration.

To carry out effective treatment, you need to decide which is better: Roxera or Atorvastatin; in addition to this question, patients also have the question of what is better: Roxera or Roxera. The emergence of these questions is associated with the high popularity of these particular drugs for lipid-lowering therapy.

The difficulty in choosing the optimal drug lies in the fact that they all have similar effects on the patient’s body. For this reason, only the attending physician can choose the optimal version of the drug based on the results of examinations and taking into account the physiological characteristics of the patient’s body.

Compatibility with other drugs

Which is better: therapy with rosuvastatin or atorvastatin, what is the difference between the drugs?

Third- and fourth-generation statins are much better compatible with other drugs. Atorvastatin should not be prescribed concomitantly with:

• gemfibrozil;
• a combination of tipranavir with ritonavir;
• telaprevir;
• cyclosporine.

Correction of the dosage of tablets is necessary when taken simultaneously with the following drugs:

• boceprivir;
• verapamil;
• digoxin;
• diltiazem;
• itraconazole;
• clarithromycin;
• colchicine;
• lopinavir with ritonavir;
• nelfinavir;
• niacin;
• omeprazole;
• ezetimibe.

Rosuvastatin tablets differ from other statins by minimal interaction with cytochrome P450 enzymes. It can, but is not advisable, be prescribed as an addition to a course of treatment with drugs with which other HMG-CoA reductase inhibitors are not compatible. Rosuvastatin preparations are not prescribed to patients taking fibrates or cyclosporine.

Review of Atorvastatin and Liprimar

Atorvastatin is a selective inhibitor of HMG-CoA reductase, which regulates the synthesis of mevalonic acid, which is part of sterol molecules.
Sterols bind to lipids to form a cholesterol molecule. The cholesterol molecule, after binding to proteins, forms lipoproteins. Depending on the amount of protein in the molecule, lipids are divided into high- and low-density molecules. Exceeding the norm of the latter becomes the cause of atherosclerotic neoplasms and impaired blood flow.

Mechanism of action of statins

Atorvastatin effectively inhibits the conversion of mevalonate to low-density lipids. The first therapeutic effect can be diagnosed 14 days after administration, and the maximum effect of the drug occurs after a month of administration and persists throughout the entire course of medication.

The absorption of the drug depends on the dosage taken, and the maximum concentration in the blood occurs 1-2 hours after taking the tablet. Bioavailability – 14%. Metabolism occurs in liver cells. The active component with metabolites is excreted through bile, and 2% of the taken dosage is excreted in urine. The half-life is 20-30 hours.

Liprimar is a lipid-lowering drug with the active component atorvastatin. The medication is an inhibitor of HMG-CoA reductase, which promotes the synthesis of mevalonate, which is part of the cholesterol molecule. This is a synthetic medication that lowers the cholesterol index of all fractions, as well as triglycerides.

By influencing the synthesis of cholesterol and reducing the LDL and LDL fractions, the drug increases the concentration of cholesterol in the HDL fraction, which protects the bloodstream from the formation of blood clots, preventing thrombosis. The drug is also an excellent prophylactic for preventing the development of stroke and heart attack.

The drug is actively used in pediatrics and is practically the only statin that is allowed to be taken by children over 8 years of age with hereditary hypercholesterolemia. Research has found that the drug does not affect the growth and formation of the body, as well as the process of puberty in adolescents. In teenage girls, the menstrual cycle is not disrupted when taking the pills.

Comparison of side effects of Roxera and Crestor

“atorvastatin

Side effects or adverse events are any adverse medical event that occurs in a subject after administration of a drug.

Roxera has more adverse effects than Crestor. This implies that the frequency of their occurrence is low in Roxera and low in Crestor. Frequency of manifestation is an indicator of how many cases of an undesirable effect from treatment are possible and registered. The undesirable effect on the body, the strength of influence and the toxic effect of drugs are different: how quickly the body recovers after taking it and whether it recovers at all. When using Roxera, the body's ability to recover faster is higher than that of Crestor.

Comparison of safety of Atoris and Liprimar

The safety of a drug includes many factors.

At the same time, in Atoris it is quite similar to Liprimar. It is important where the drug is metabolized: drugs are excreted from the body either unchanged or in the form of products of their biochemical transformations. Metabolism occurs spontaneously, but most often involves major organs such as the liver, kidneys, lungs, skin, brain and others. When assessing metabolism in Atoris, as well as in Liprimar, we look at which organ is the metabolizing organ and how critical the effect on it is.

The risk-benefit ratio is when the prescription of a drug is undesirable, but justified under certain conditions and circumstances, with the obligatory observance of caution in use. At the same time, Atoris does not have any risks when used, just like Liprimar.

Also, when calculating safety, it is taken into account whether only allergic reactions occur or possible dysfunction of the main organs. In other matters, as well as the reversibility of the consequences of using Atoris and Liprimar.

Negative feedback from patients

Despite a decent number of positive opinions about the drug Atoris, patient reviews, unfortunately, can also be negative, but they are in the minority. Such responses are associated with the following:

1. The high cost of the medicine.

There are patients who consider the price to be a disadvantage of this medication. However, in reality, all such drugs are expensive. And there is no way to fight this.

2. The medicine does not work.

There are also cases when people who took the medication complained that money was thrown away and there was no effect. But it turns out that in such patients, cholesterol increased significantly before taking the pills. And with the start of therapy with Atoris, the level of this lipid substance stopped increasing. So what then is its ineffectiveness? After all, it temporarily stopped the process of increasing cholesterol. Keep in mind that therapy with this remedy is quite lengthy.

3. Side effects after taking Atoris.

A Swiss high-quality drug that can reduce LDL levels by 50% and cholesterol by 40%. The effect is noticeable already 3 weeks after use, and the maximum impact is achieved after a month.

Treatment begins with a small dose of 10 mg of the active substance per day, if necessary increasing it after 3-4 weeks, based on a blood test. As with other statins, patients often report side effects such as insomnia, loose stools, and muscle weakness. Prices for Swiss Tulip start at 255 rubles for 30 tablets with a dosage of 10 mg.

Novostat

The most modern and cheaper replacement for Atoris from the Russian manufacturer ATOLL. It is produced in the form of capsules and contains slightly different auxiliary components, which allows you to achieve a faster and more noticeable effect from therapy.

The initial dosage remains unchanged – 10 mg/day. However, before using the drug, it is recommended to switch to a standard hypocholesterol diet, which must be followed throughout the entire period of treatment. Prices for Novostatin start at 330 rubles.

Liprimar

The Irish analogue is not as cheap, but extremely safe and much more effective, with minimal side effects. In fact, this is the same lipid-lowering and hypocholesterolemic drug from the pharmaceutical company Pfizer, known for its high production technologies and the use of compositions that are as gentle as possible on the body, which is especially important for long-term treatment. In the case of high cholesterol, treatment with statins can last from several months to more than a year.

At the same time, there is also a significant disadvantage of this drug, which is its high cost. Prices for Liprimar in Russian pharmacies start at 700 rubles for 10 tablets of the minimum dosage.

Description of drugs

To figure out which medicine is more effective and safer, you should study the composition of both, as well as indications and contraindications for use.

Compound

Atorvastatin

The active component of Atorvastatin is a chemical compound of the same name, which belongs to the group of 3rd generation statins. These substances are involved in the process of cholesterol production and slow it down. In addition, they reduce the content of low-density lipoproteins (LDL) in the blood - protein-fat complexes deposited on the walls of blood vessels. The tablets, in addition to Atorvastatin in the form of a calcium salt, contain formative auxiliary ingredients and enteric coating components.

Liprimar

The active ingredient of Liprimar is also Atorvastatin, but there are more options for its dosage in one tablet. The composition of the remaining auxiliary ingredients does not differ.

Mechanism of action

In addition to cholesterol, an excess of low-density protein-fat compounds (LDL) also poses a danger to the cardiovascular system. They settle on the walls of blood vessels, forming so-called cholesterol plaques. As a result, atherosclerosis develops, a disease in which the lumen of blood vessels decreases and their walls are destroyed. This condition is fraught with hemorrhages (strokes), so it is necessary to control the amount of “bad” cholesterol.

Atorvastatin in both drugs, after administration, enters the blood and liver cells. In the first case, it simply destroys harmful fats. And in the liver, where cholesterol production occurs, the medicine is involved in this process and slows it down. Atorvastatin and Liprimar must be taken in cases where diet and exercise are ineffective (in hereditary forms of hypercholesterolemia).

Indications

Atorvastatin and Liprimar are prescribed for the same indications:

• hereditary hypercholesterolemia of various types that cannot be treated with diet and exercise;
• condition after a heart attack (death of a section of the heart muscle caused by a sudden disruption of blood circulation);
• coronary heart disease - damage to its muscle fibers and disruption of work due to poor blood supply;
• angina pectoris is a type of previous disease characterized by attacks of acute pain;
• diabetes;
• high blood pressure (hypertension);
• atherosclerosis.

Contraindications

You should not take Atorvastatin or Liprimar:

• with hepatitis (liver inflammation) in the acute stage;
• with intolerance to drug components;
• children and adolescents under 18 years of age (or up to 10, with familial hypercholesterolemia);
• pregnant women;
• nursing;
• women planning a pregnancy or who do not have adequate protection against conception;
• persons with a significant increase in the activity of liver enzymes - proteins that ensure metabolism in the cells of this organ.

The drugs are used with caution to treat patients with liver disease and alcohol dependence.

Release forms and price

Domestic Atorvastatin is sold in pharmacies. The medicine is produced by several pharmaceutical companies, which explains the wide range of prices for it. The cost is also affected by the number of enteric tablets in the package and the dosage of the active substance:

• 10 mg, 30, 60 and 90 pcs. in a pack - 141, 240 and 486 rubles. respectively;
• 20 mg, 30, 60 and 90 pcs. – 124, 268 and 755 rubles;
• 40 mg, 30 pcs. – from 249 to 442 rubles.

Liprimar is an American enteric tablet. The cost of the drug is determined in accordance with its dosage and quantity:

• 10 mg, 30 or 100 pieces per pack – 737 and 1747 rubles;
• 20 mg, 30 or 100 pcs. – 1056 and 2537 rubles;
• 40 mg, 30 tablets – 1110 rubles;
• 80 mg, 30 tablets. – 1233 rubles.

The principle of action of the drugs

The principle of action of Atorvastatin and Liprimar is identical, because both medications contain one active ingredient in their composition. The active ingredient atorvastatin lowers the lipoprotein index in the blood by inhibiting HMG-CoA reductase in liver cells, which reduces the synthesis of cholesterol molecules and increases the concentration of LDL receptors, which intensively absorb lipids and enhance the catabolism of the LDL fraction.

The third generation of statin drugs is distinguished by its ability to lower cholesterol in homozygous genetic hypercholesterolemia, when other drugs are ineffective.

The effectiveness of medications is manifested in mixed forms of dyslipidemia, as well as triglyceridemia with a non-familial type of dysbetalipoproteinemia. The therapeutic effect of atorvastatin on lipid metabolism is as follows:

• decrease in total cholesterol by more than 35%;
• decrease in LDL fraction - by 45-50%
• decrease in triglyceride molecules – by 10-11%;
• decrease in apo-B lipoproteins – by 40-42%;
• increase in HDL - by 10-14%
• increase in apolipoprotein index (apo-A) – by 3.5-4%;
• decrease in the atherogenic coefficient between apo-B and apo-A.

Rosecard

Rosucard is prescribed for:

• primary hypercholesterolemia;
• heterozygous hereditary hypercholesterolemia;
• supplementing the diet;
• hereditary hypercholesterolemia;
• progression of atherosclerosis.

Can be used as a prophylactic against major cardiovascular complications:

• arterial revascularization;
• heart attack;
• stroke;
• coronary heart disease (CHD).

Contraindicated for persons suffering from:

• hypersensitivity to rosuvastatin;
• progression of liver diseases;
• liver failure;
• hereditary lactose intolerance;
• renal failure;
• myopathy.

Rosucard should not be taken by those with creatine deficiency, pregnant women and children under 18 years of age. Nursing mothers should also refrain from taking the medication, since there is no reliable information regarding the effect of the drug components on children through breast milk. Accidental diagnosis - pregnancy signals discontinuation of the drug.

Affects the ability to drive vehicles

Therefore, during the period of taking it, you should drive with extreme caution and carry out activities that require increased concentration of attention with a quick psychomotor reaction. The average price for the drug is 400 rubles

Indications and contraindications

In accordance with the instructions for use, medications based on the active substance atorvastatin are prescribed for the following pathologies:

• primary form of genetic hypercholesterolemia;
• heterozygous and homozygous hypocholesterolemia in addition to dietary nutrition;
• combined hypercholesterolemia;
• dyslipidemia and dysbetalipoproteinemia in addition to an anti-cholesterol diet;
• hypertriglyceridemia in combination with an anti-cholesterol diet;
• hypertonic disease;
• low HDL fraction;
• systemic atherosclerosis.

Combined hypercholesterolemia

Medications are also prescribed in the following situations:

• with a hereditary predisposition of the body to the accumulation of lipids, regardless of the patient’s gender and age;
• IHD, unstable angina and other cardiac diseases;
• with coronary insufficiency;
• men over 45 years old;
• women during menopause;
• for patients with nicotine and alcohol addiction.

It is also relevant to use medications as preventive measures to prevent such pathologies:

• primary prevention of heart attack and stroke;
• post-infarction and post-stroke period;
• after vascular surgery.

Liprimar and Atorvastatin are not prescribed for the following disorders in the body:

• high sensitivity to the components of the drug;
• cirrhosis;
• liver failure;
• impaired malabsorption;
• increased transaminase levels;
• cataract;
• pregnancy and lactation;
• children under 18 years of age (Liprimar is not prescribed to children under 8 years of age).

Statins are prescribed very carefully for:

• low blood pressure index, as well as patients over 65-70 years old;
• hypothyroidism;
• chronic alcoholism;
• diabetes mellitus of the first and second types.

Symptoms of hypothyroidism

Atorvastatin crosses the placental barrier. Cholesterol is very important for the intrauterine development of the fetus, so statins have a detrimental embryonic effect on the fetus if a woman takes medications. For this reason, during pregnancy, women are prohibited from being prescribed HMG-CoA reductase inhibitors. Statins are also detected in breast milk, so therapy with statin drugs is also contraindicated for women during lactation.

Similar preparations based on another active ingredient

Atorvastatin belongs to the statin drug group, but it is not the only drug on their list. There are more advanced dosage forms - 4th generation statins. They have a similar, pronounced effect and fewer side effects. Below are some of them.

"Rosuvastatin-SZ"

Russian medicine. , hence the “NW” marking in its name. The substance itself at the heart of the drug is rosuvastatin. Its mechanism of action is similar, but the medication itself is more potent and its safety profile is much higher.

https://www.youtube.com/watch?v=S3fNC9uCZ04

Estimated cost: 150 rubles (for the smallest package). Release forms: 5, 10, 20, 40 mg. The number of tablets in a package can also be selected based on material capabilities. "Rosuvastatin-SZ" is produced in 30, 60, 90 tablets.

Beneficial features

The main property of Liprimar is its hypolipidemic properties. The drug helps reduce the production of enzymes responsible for cholesterol synthesis. This leads to a decrease in the production of cholesterol by the liver, accordingly its level in the blood drops, and the functioning of the cardiovascular system improves.

The medicine is prescribed to people with hypercholesterolemia that does not respond to diet and other cholesterol-lowering medications. After a course of therapy, cholesterol levels drop by 30-45%, and LNDL by 40-60%, and the amount of a-lipoprotein in the blood increases.

The use of Liprimar helps reduce the development of complications of coronary artery disease by 15%, mortality from cardiac pathologies falls, and the risk of heart attacks and dangerous attacks of angina is reduced by 25%. No mutagenic or carcinogenic properties have been identified.

The most well-known analogues and substitutes are cheaper than Atoris

Despite the fact that the doctor prescribes a specific drug, the patient can always choose a cheaper analogue from the same pharmaceutical group (in this case, from the group of statins) and take it, observing the prescribed dosage of the active substance.

Atorvastatin

The closest analogue, much cheaper than Atoris. In essence, this is the same lipid-lowering drug, which is an active substance with a smaller number of auxiliary components compared to Atoris. It is produced by several domestic pharmaceutical companies, such as Vertex, Biocom, AlsiPharma, which explains its lower cost. Release form: tablets with a dosage of 10 to 80 mg.

The initial dosage is still the same – 10 mg/day. The maximum therapeutic effect is noticeable after 4 weeks; with longer treatment, the dynamics of therapy are maintained. Atorvastatin is available by prescription. Prices in Russia start from 80 rubles for 30 tablets with a dosage of 10 mg.

Torvacard

Manufactured and marketed by the pharmaceutical company Zentiva, located in the Czech Republic. Available in dosages of 10, 20 and 40 mg, 30 or 90 tablets. According to medical practice, the medicine reduces cholesterol levels by 30-40%, and the level of low and very low density lipoproteins by 40-60%. The maximum effect is achieved when used simultaneously with a low-cholesterol diet, treatment of obesity and increased physical activity.

Since the active substance is the same atorvastatin, the initial dosage of the drug remains the same: 10 mg/day. A significant effect is noticeable after 1-2 months of use. Prices in Russian pharmacies for Torvacard 10 mg dosage start at 260 rubles.

Tulip

A Swiss high-quality drug that can reduce LDL levels by 50% and cholesterol by 40%. The effect is noticeable already 3 weeks after use, and the maximum impact is achieved after a month.

Treatment begins with a small dose of 10 mg of the active substance per day, if necessary increasing it after 3-4 weeks, based on a blood test. As with other statins, patients often report side effects such as insomnia, loose stools, and muscle weakness. Prices for Swiss Tulip start at 255 rubles for 30 tablets with a dosage of 10 mg.

Novostat

The most modern and cheaper replacement for Atoris from the Russian manufacturer ATOLL. It is produced in the form of capsules and contains slightly different auxiliary components, which allows you to achieve a faster and more noticeable effect from therapy.

The initial dosage remains unchanged – 10 mg/day. However, before using the drug, it is recommended to switch to a standard hypocholesterol diet, which must be followed throughout the entire period of treatment. Prices for Novostatin start at 330 rubles.

Liprimar

The Irish analogue is not as cheap, but extremely safe and much more effective, with minimal side effects. In fact, this is the same lipid-lowering and hypocholesterolemic drug from the pharmaceutical company Pfizer, known for its high production technologies and the use of compositions that are as gentle as possible on the body, which is especially important for long-term treatment. In the case of high cholesterol, treatment with statins can last from several months to more than a year.

At the same time, there is also a significant disadvantage of this drug, which is its high cost. Prices for Liprimar in Russian pharmacies start at 700 rubles for 10 tablets of the minimum dosage.

Liprimar

Synthetic lipid-lowering drug. Atorvastatin is a selective competitive inhibitor of HMG-CoA reductase, a key enzyme that converts 3-hydroxy-3-methylglutaryl-CoA into mevalonate, a precursor of steroids, including cholesterol.

In patients with homozygous and heterozygous familial hypercholesterolemia, non-familial forms of hypercholesterolemia and mixed dyslipidemia, atorvastatin reduces the content of total cholesterol (C), LDL-C and apolipoprotein B (apo-B) in the blood plasma, as well as the content of VLDL-C and TG, causing unstable increase in HDL-C levels.

Atorvastatin reduces the concentration of cholesterol and lipoproteins in the blood plasma by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver and increasing the number of hepatic LDL receptors on the cell surface, which leads to increased uptake and catabolism of LDL-C.

Atorvastatin reduces the formation of LDL-C and the number of LDL particles. Causes a pronounced and persistent increase in the activity of LDL receptors, combined with favorable qualitative changes in LDL particles. Reduces the level of LDL-C in patients with homozygous hereditary hypercholesterolemia, resistant to therapy with other lipid-lowering drugs.

Atorvastatin in doses of 10-80 mg reduces total cholesterol by 30-46%, LDL-C by 41-61%, apo-B by 34-50% and TG by 14-33%. Treatment results are similar in patients with heterozygous familial hypercholesterolemia, non-familial forms of hypercholesterolemia and mixed hyperlipidemia, incl. in patients with non-insulin-dependent diabetes mellitus.

In patients with isolated hypertriglyceridemia, atorvastatin reduces the levels of total cholesterol, LDL-C, VLDL-C, apo-B and TG and increases the level of HDL-C. In patients with dysbetalipoproteinemia, it reduces the level of intermediate-density lipoprotein cholesterol.

In patients with hyperlipoproteinemia types IIa and IIb according to the Fredrickson classification, the average increase in HDL-C levels during treatment with atorvastatin (10-80 mg), compared with the baseline value, is 5.1-8.7% and is independent of dose. There is a significant dose-dependent decrease in the ratios: total cholesterol/HDL-C and LDL-C/HDL-C by 29-44% and 37-55%, respectively.

Liprimar® at a dose of 80 mg significantly reduces the risk of ischemic complications and mortality rate by 16% after a 16-week course, and the risk of re-hospitalization for angina pectoris accompanied by signs of myocardial ischemia by 26%. In patients with different initial levels of LDL-C, Liprimar® causes a reduction in the risk of ischemic complications and death (in patients with myocardial infarction without a Q wave and unstable angina, men and women, patients under and over 65 years of age).

A decrease in plasma LDL cholesterol levels correlates better with the dose of the drug than with its concentration in the blood plasma.

The therapeutic effect is achieved 2 weeks after the start of therapy, reaches a maximum after 4 weeks and persists throughout the entire period of therapy.

Prevention of cardiovascular diseases

In the Anglo-Scandinavian study of cardiovascular complications, lipid-lowering branch (ASCOT-LLA), the effect of atorvastatin on fatal and non-fatal outcomes of coronary artery disease found that the effect of treatment with atorvastatin at a dose of 10 mg significantly exceeded the effect of placebo, and therefore it was decided to early termination of the study after 3.3 years instead of the expected 5 years.

Atorvastatin significantly reduced the development of the following complications:

There were no significant reductions in overall mortality and mortality from cardiovascular causes, although positive trends were observed.

Diabetes

The pooled study of the effects of atorvastatin in patients with type 2 diabetes (CARDS) on fatal and non-fatal cardiovascular disease outcomes showed that atorvastatin therapy, regardless of patient gender, age or baseline LDL-C level, reduced the risk of developing the following cardiovascular events :

Atherosclerosis

The Reversal of Coronary Atherosclerosis with Intensive Lipid-Lowering Therapy (REVERSAL) study with atorvastatin 80 mg in patients with coronary artery disease found that the average reduction in total atheroma volume (the primary outcome measure) from the start of the study was 0.4%.

Recurrent stroke

The Intensive Reduction in Cholesterol Levels (SPARCL) program found that atorvastatin 80 mg/day reduced the risk of recurrent fatal or nonfatal stroke in patients with a history of stroke or transient ischemic attack without a history of coronary artery disease by 15% compared with placebo. At the same time, the risk of major cardiovascular complications and revascularization procedures was significantly reduced. A reduction in the risk of cardiovascular events during atorvastatin therapy was observed in all groups except the one that included patients with primary or recurrent hemorrhagic stroke (7 in the atorvastatin group versus 2 in the placebo group).

Hemorrhagic stroke

In patients treated with atorvastatin 80 mg, the incidence of hemorrhagic or ischemic stroke (265 versus 311) or coronary artery disease (123 versus 204) was lower than in the control group.

Secondary prevention of cardiovascular complications

The Treatment of the New Targeted Trial (TNT) compared the effect of atorvastatin at doses of 80 mg/day and 10 mg/day on the risk of cardiovascular events in patients with clinically confirmed coronary artery disease.

Atorvastatin at a dose of 80 mg significantly reduced the development of the following complications:

Pharmacokinetics

Suction

Atorvastatin is rapidly absorbed after oral administration; Cmax is reached after 1-2 hours. The degree of absorption and plasma concentrations of atorvastatin increase in proportion to the dose. The absolute bioavailability of atorvastatin is about 14%, and the systemic bioavailability of HMG-CoA reductase inhibitory activity is about 30%. Low systemic bioavailability is due to first-pass metabolism in the gastrointestinal mucosa and/or during the “first pass” through the liver. Food reduces the rate and extent of absorption by approximately 25% and 9%, respectively (as evidenced by Cmax and AUC), but the reduction in LDL-C is similar to that observed with fasting atorvastatin. Despite the fact that after taking atorvastatin in the evening, its plasma concentration is lower (Cmax and AUC by approximately 30%) than after taking it in the morning, the decrease in LDL-C does not depend on the time of day at which the drug is taken.

Distribution

The average Vd of atorvastatin is about 381 l. The binding of atorvastatin to plasma proteins is at least 98%. The ratio of atorvastatin content in red blood cells/blood plasma is about 0.25, i.e. Atorvastatin penetrates red blood cells poorly.

Metabolism

Atorvastatin is extensively metabolized to form ortho- and parahydroxylated derivatives and various beta-oxidation products. In vitro, ortho- and parahydroxylated metabolites have an inhibitory effect on HMG-CoA reductase comparable to that of atorvastatin. Approximately 70% of the decrease in HMG-CoA reductase activity is due to the activity of circulating metabolites. The results of in vitro studies suggest that the CYP3A4 isoenzyme plays an important role in the metabolism of atorvastatin. This is confirmed by an increase in the concentration of atorvastatin in human plasma while taking erythromycin, which is an inhibitor of this isoenzyme. In vitro studies have also shown that atorvastatin is a weak inhibitor of the CYP3A4 isoenzyme. Atorvastatin does not have a clinically significant effect on the plasma concentration of terfenadine, which is metabolized mainly by the CYP3A4 isoenzyme; therefore, a significant effect of atorvastatin on the pharmacokinetics of other substrates of the CYP3A4 isoenzyme is unlikely.

Removal

Atorvastatin and its metabolites are excreted mainly in bile after hepatic and/or extrahepatic metabolism (atorvastatin does not undergo significant enterohepatic recirculation). T1/2 is about 14 hours, while the inhibitory effect of the drug on HMG-CoA reductase is approximately 70% determined by the activity of circulating metabolites and persists for about 20-30 hours due to their presence. After oral administration, less than 2% of the atorvastatin dose is found in the urine.

Pharmacokinetics in special clinical situations

Plasma concentrations of atorvastatin in patients over 65 years of age are higher (Cmax approximately 40%, AUC approximately 30%) than in younger adult patients. There were no differences in the safety, effectiveness, or achievement of lipid-lowering treatment goals in elderly patients compared with the general population.

Pharmacokinetic studies of the drug have not been conducted in children.

Plasma concentrations of atorvastatin in women differ (Cmax is approximately 20% higher and AUC is 10% lower) from those in men.

Impaired renal function does not affect the plasma concentration of atorvastatin or its effect on lipid metabolism. In this regard, no dose changes are required in patients with impaired renal function.

Atorvastatin is not excreted during hemodialysis due to intense binding to plasma proteins.

Atorvastatin concentrations are significantly increased (Cmax and AUC approximately 16-fold and 11-fold, respectively) in patients with alcoholic cirrhosis (Child-Pugh class B).

Analogues of the drug Roxera

Analogues are determined by structure:

1. Rosecard.
2. Mertenil.
3. Rustor.
4. Roseart.
5. Rozulip.
6. Crestor.
7. Rosuvastatin.
8. Tevastor.
9. Roseystar.
10. Akorta.

The group of statins includes analogues:

1. Kholvasim.
2. Syncard.
3. Holetar.
4. Torvacard.
5. Lipostat.
6. Zokor forte.
7. Apexstatin.
8. Symvacol.
9. Lipona.
10. Roseart.
11. Aterostat.
12. Rosuvastatin.
13. Pravastatin.
14. Anvist.
15. Atomax.
16. Lipoford.
17. Rosecard.
18. Simvastol.
19. Simlo.
20. Torvalip.
21. Leskol.
22. Cardiostatin.
23. Rozulip.
24. Rovacor.
25. Zokor.
26. Basil.
27. Ator.
28. Liprimar.
29. Lovastatin.
30. Novostat.
31. Simgal.
32. Crestor.
33. Liptonorm.
34. Torvazin.
35. Rustor.
36. Torvas.
37. Atorvox.
38. Atorvastatin.
39. Tevastor.
40. Simvacard.
41. Atocord.
42. Lipobay.
43. Mertenil.
44. Zorstat.
45. Vasator.
46. Lovasterol.
47. Atoris.
48. Lovacore.
49. Tulip.
50. Simvastatin.
51. Actalipid.

The best drugs of the 3rd and 4th generations

On the pharmaceutical market, statins of the third and fourth generation are represented by both original drugs - Liprimar (atorvastatin) and Crestor (rosuvastatin), and similar copies, the so-called. generics, which are made from the same active substance, but under a different name (INN):

• atorvastatin – Tulip, Atomax, Liptonorm, Torvacard, Atoris, Atorvastatin;
• rosuvastatin - Roxera, Rosucard, Mertenil, Rozulip, Lipoprime, Rozart.

It is important to understand, despite the fact that Atorvastatin and Rosuvastatin are not the same thing, they should be taken equally seriously: carefully analyze the health of the liver and kidneys, both before and after, and also strictly follow the treatment regimen prescribed by the doctor, diet and physical activity

Comparison of the effectiveness of Atorvastatin-teva and Atoris

The effectiveness of Atorvastatin-teva is quite similar to Atoris - this means that the ability of the drug substance to provide the maximum possible effect is similar. For example, if the therapeutic effect of Atorvastatin-teva is more pronounced, then using Atoris even in large doses will not achieve this effect. Also the speed of therapy is an indicator of the speed of therapeutic action in Atorvastatin-teva and Atoris are approximately the same. And bioavailability, that is, the amount of a drug reaching its site of action in the body, is similar. The higher the bioavailability, the less it will be lost during absorption and use by the body.

Interaction with other drugs and analogues

When statins are taken together with the drug Cyclosporine, myopathy and rhabdomyolysis develop, and the risk of developing these pathologies after Erythromycin also increases.

If you take Digoxin and statins at the same time, then the concentration of Digoxin increases. The concentration of oral contraceptives in the body increases when used together with statins. When taking Atorvastatin, or Liprimar and Warfarin, the prothrombin time decreases and must be constantly monitored.

It is also not recommended to take statin tablets and grapefruit juice.

Analogs of third-generation satins based on the active component atorvastatin are medications of this generation, as well as drugs based on simvastatin:

1. Atoris is effective for homozygous hypercholesterolemia and triglyceridemia.
2. Vasostat is a drug prescribed for systemic atherosclerosis and hypercholesterolemia of various etiologies, as well as for the prevention of cerebrovascular pathologies.
3. Zocor - the use of the drug reduces the risk of developing cardiac diseases and effectively reduces the cholesterol index.

Crestor or Roxera: which is better and what is the difference between drugs for high cholesterol?

High cholesterol at the present stage of development of society is one of the most common problems among the older generation. In recent years, the presence of high cholesterol has been increasingly recorded among the younger generation.

The reasons for the rejuvenation of pathology are the frequent occurrence of stressful psychological stress on the body, a violation of the nutritional culture, eating a large amount of potentially dangerous foods, as well as leading a sedentary lifestyle. All of these factors provoke metabolic disorders in the body.

To eliminate the emerging pathological condition, it is necessary to select a good and effective medication for therapeutic correction of cholesterol levels in the blood plasma.

To reduce high cholesterol levels in the body, doctors most often recommend the use of medications belonging to the group of statins.

Two drugs in this group are especially popular - Crestor or Roxera.

These lipid-lowering drugs are produced by the manufacturer in the form of tablets for oral administration.

To carry out effective treatment, you need to decide which is better: Roxera or Atorvastatin; in addition to this question, patients also have the question of what is better: Roxera or Roxera. The emergence of these questions is associated with the high popularity of these particular drugs for lipid-lowering therapy.

The difficulty in choosing the optimal drug lies in the fact that they all have similar effects on the patient’s body. For this reason, only the attending physician can choose the optimal version of the drug based on the results of examinations and taking into account the physiological characteristics of the patient’s body.

Features of the drug Roxera

Roxera is a strong lipid-lowering drug. The main active ingredient of this medication is rosuvastatin.

Indications for the use of this medication are the presence of hypercholesterolemia in the patient in various forms - primary and mixed.

Roxera is also used in the treatment of diseases such as atherosclerosis. The use of the drug prevents the development of serious disorders associated with high levels of cholesterol in the blood plasma.

The most common and popular analogues of Roxera among patients are drugs such as Atoris and Crestor.

These drugs have the same main active compound - rosuvastatin.

Roxera is a medicine developed by Russian pharmacists.

Roxera is available in the form of tablets intended for oral administration.

The drug tablets are taken orally and washed down with a sufficient amount of water.

Dosages of Roxers used in treatment are similar to those used in treatment with Crestor.

The following situations are contraindicated for use:

1. Hypersensitivity to the main component or auxiliary compounds.
2. The period of bearing a child and the period of breastfeeding.
3. The patient's age is under 18 years.
4. The patient has lactose intolerance and a deficiency of lactase in the body.
5. Myopathy.
6. Kidney and liver failure.

When using the drug, side effects such as dizziness may develop; headache; skin rash; development of jaundice; development of hepatitis; memory loss; pain in the abdominal area; the occurrence of constipation and diarrhea; nausea; myopathies.

The main analogues of Roxera based on the active ingredient are:

• Rozulip.
• Rosecard.
• Crestor.
• Tevastor.
• Mertenil.
• Akorta.
• Rustor.

Comparison of ease of use of Atoris and Liprimar

This includes dose selection taking into account various conditions and frequency of doses. At the same time, it is important not to forget about the release form of the drug; it is also important to take it into account when making an assessment.

The ease of use of Atoris is approximately the same as Liprimar. However, they are not convenient enough to use.

The drug ratings were compiled by experienced pharmacists who studied international research. The report is generated automatically.

Last update date: 2020-12-04 13:44:18

Roxera - analogues

Lipid-lowering drugs are vital for those people who need to constantly monitor their blood cholesterol levels. The drug Roxera and its analogues were created specifically for this purpose. Controlling the amount of cholesterol in the body will help prevent a considerable number of diseases and ensure good health.

Indications for use of Roxera and its analogues

The main active ingredient of Roxera is rosuvastin. This is an inhibitor of a special enzyme, HMG-CoA reductase, which is involved in the formation of cholesterol. In addition to rosuvastine, Roxera includes the following auxiliary components:

• magnesium stearate;
• crospovidone;
• anhydrous lactose;
• anhydrous colloidal silica;
• microcrystalline cellulose.

Both Roxera and analogue drugs act in the liver, the organ where cholesterol is synthesized. The drugs effectively increase the number of liver receptors, thereby reducing the level of low-density lipoprotein cholesterol.

Drugs are prescribed for the following pathologies:

• primary hypercholesterolemia;
• mixed hypercholesterolemia;
• atherosclerosis;
• homozygous hypercholesterolemia;
• cardiac ischemia;
• arterial hypertension;
• complications after vascular diseases.

Which is better - Roxera, Atoris or Crestor?

Despite the fact that Roxera is considered an effective and safe drug, for one reason or another the medication is not suitable for everyone. Such patients require similar medications. Atoris and Crestor have become the most popular analogues of Roxera. The principle of action of these drugs is almost identical. The main difference is in the composition.

The main active ingredient in Roxer and Crestor is rosuvastine. That is, these drugs are almost the same. They differ in manufacturer and, accordingly, in price - Crestor is much more expensive. Some patients note that Crestor acts faster, but this largely depends on the characteristics of the body, complexion, and diagnosis.

In practice, only the experimental method helps determine which drug is more effective in a particular case. It often happens that some drugs are ideal for someone, but do not work at all for others.

How to replace Roxera?

Of course, in addition to the drugs Atoris and Crestor, there are other generics of Roxera. Moreover, the list is impressive:

• Rosecard;
• Roseystar;
• Tevastor;
• Emstat;
• Rozulip;
• Atorvastin;
• Roseart;
• Mertenil;
• Rovics;
• Rozusta;
• Fastong;
• Astin;
• Atokor;
• Vazotor;
• Basilip;
• Romazik;
• Klyvas;
• Atorvakor;
• Attormak;
• Simvacard;
• Novostat;
• Holetar;
• Torvas;
• Vabadine;
• Zokor;
• Livazo;
• Kardak;
• Liprimar;
• Simlo;
• Pravastatin and others.

The effect of taking statins occurs a few weeks after the start of treatment. The dosage and duration of the treatment course for each patient is determined individually.

Both Roxera and its analogues are contraindicated for certain categories of patients:

1. Pregnant and nursing mothers should not take statins.
2. Treatment with Roxera and its analogues is contraindicated in children under 18 years of age.
3. Statin drugs are not suitable for people with kidney pathologies.
4. Roxera and its analogues can harm patients with neuromuscular diseases.

Roxera - indications for use Roxera is a drug that is vital for people with high cholesterol or those who are prone to this problem. This lipid-lowering drug has established itself as one of the best statins. To whom and in what cases Roxera is prescribed, we will tell you in the article. Rezalut is one of the effective hepatoprotective agents, which is widely used in the treatment and prevention of liver diseases. However, less expensive analogues can be used, the choice of which depends on the specific case. Rezalut - indications for use Rezalut is a hepatoprotective agent containing phospholipids necessary to restore liver function. The medicine is used for common liver diseases, as well as as a prophylaxis against alcohol abuse and fatty foods. More than half of the world's women suffer from irritable bowel syndrome of varying intensity. Duspatalin is often prescribed to relieve spastic attacks.

Find out from our new article which drugs can replace it, and which ones you should pay special attention to.

Causes and development of atherosclerosis

The main reason for the clinical manifestations of obliterating atherosclerosis is a person’s ability to live more than 40 years. Early mortality in previous centuries did not allow diagnosing arterial damage. Most diseases that lead to death or disability are in one way or another associated with atherosclerosis. Age-related atherosclerosis appears in all people sooner or later. However, a number of patients exhibit an innate tendency to atherosclerosis - hyperlipedemia (hereditary increase in cholesterol in the blood).

The main changes in atherosclerosis develop in the intima (inner lining) of the arteries. Cholesterol and fatty inclusions (lipids) begin to be deposited here, forming yellowish spots on the inner wall of the vessel. Subsequently, the formation of an atherosclerotic plaque occurs. Platelets and clots of fibrin and calcium salts settle on the plaques.

With an abundant accumulation of lipids and calcium, blood circulation in the plaques is impaired, the necrosis of which causes the appearance of atheroma cavities filled with disintegrating masses. The artery wall in the area of ​​such a plaque is rock hard and crumbles easily. Crumb-like masses are rejected into the lumen of the vessel. Getting through the bloodstream into the underlying blood vessels, pieces of crumbled atherosclerotic plaque can cause blockage (embolism) and lead to thrombosis of the arteries of the limb with the development of gangrene (death). In addition, a large plaque leads to a significant disruption of blood flow, which reduces the delivery of oxygen to the tissues. During physical activity, muscles that do not receive sufficient nutrition refuse to work, pain occurs, which disappears only after rest. A large plaque promotes the development of a blood clot at the site of narrowing of the vessel, which can lead to acute ischemia and gangrene.

Drug therapy can be aimed at the causes of the disease (etiotropic treatment), the mechanisms of its development (pathogenetic treatment), the symptoms of the disease (symptomatic therapy) and the prevention of complications. The treatment of vascular patients should use a regimen that addresses all aspects of the disease.

Etiotropic and pathogenetic treatment.

Obliterating atherosclerosis . Treatment is aimed at preventing the development of atherosclerotic plaques. In addition to diet, drugs that reduce high cholesterol levels - statins - are used. Their list is quite extensive. In our practice, we use lovastatin, pravastatin, simvastatin, fluvastatin, atorvastatin, rosuvastatin. Statins have vascular effects. At the level of the vascular wall, by reducing the formation of cholesterol and low-density lipoproteins, they reduce the inclusion of cholesterol in the vascular subintima, help stabilize existing atherosclerotic plaques by reducing the lipid core, and therefore reduce the risk of plaque rupture and thrombus formation. Improvement in the functional state of the vascular endothelium during statin therapy is associated not only with their main effect, but also with pleiotropic effects. Taking statins should be long-term.

Diabetic macroangiopathy. In addition to statin therapy, the drug Vessel Due F, an organic glypolysaccharide, which helps restore the endothelium and reduces the risk of vascular thrombosis, is used to improve the condition of the vascular wall. To treat neuropathy in patients with diabetes, B vitamins (milgamma) and thioctacid are used.

Thromboangiitis obliterans (Buerger's disease) is an inflammatory disease of the arteries. For pathogenetic treatment, anti-inflammatory drugs are used - adrenal hormones in shock doses (pulse therapy). Most often, methylprednisolone (solu-medrol) is used for a short course. Targeted pulse therapy can improve the prognosis for patients with obliterating endarteritis.

Drugs that improve blood flow and affect collateral circulation.

Prostaglandins (vazaprostan, alprostan, ilomedine).
These drugs have a vasodilating effect on small arterioles, which increases the volume of blood flowing through the tissue. Sometimes this effect allows you to stop critical ischemia and delay the development of gangrene. However, without restoring the main blood flow, these drugs rarely help save a limb when gangrene develops. The drugs are antispasmodics. Modern data on such antispasmodics as papaverine, noshpa, nicotinic acid indicate their ineffectiveness and even harmfulness for patients with obliterating diseases. By dilating large unaffected arteries, they cause steal in small vessels and aggravate arterial insufficiency, and therefore should be excluded from the arsenal of vascular surgeons.

Pentoxifylline (trental, vasonite) is still widely used in domestic clinical practice, although many studies have shown their low effectiveness.

Cilastozol (Pletal) is a drug with a proven effect in intermittent claudication. However, it is not registered in the Russian Federation.

Actovegin and solcoseryl are drugs popular in domestic practice (deproteinized extracts from cattle plasma) contain a set of vitamins and minerals, some plasma hormones. Unfortunately, their effect does not meet expectations. In our practice, these drugs are not used.

Neovasculgen is a new genetic drug that stimulates the production of endothelial growth factor in tissues. According to the creators, it should stimulate the development of collateral circulation. Our limited experience does not confirm the effectiveness of the drug in patients with critical ischemia due to Buerger's disease. The high cost of the drug does not allow large-scale research into this issue.

Symptomatic therapy.

Implies a reduction in the symptoms of vascular diseases. Effective pathogenetic treatment helps eliminate the symptoms of chronic arterial insufficiency. In critical ischemia, pain relief is an important aspect of treatment. For these purposes, non-narcotic analgesics (ketorol, baralgin, diclofenac) are used. For neuralgic pain, Finlepsin and other sedatives are prescribed. In difficult cases, it is possible to prescribe narcotic analgesics (tramadol, promedol, morphine) or prolonged epidural anesthesia.

Prevention of complications.

The main complication associated with obliterating diseases is arterial thrombosis with the development of acute limb ischemia. Currently, the possibilities of modern therapy make it possible to significantly reduce the risk of thrombosis. The most effective drugs are clopidogrel (Plavix, Zilt, Thrombostop). Aspirin preparations (thromboass, cardiomagnyl) can be used in a dose of at least 100 mg per day, but they are weaker. In patients with a tendency to venous thrombosis and atrial fibrillation, indirect anticoagulants (warfarin), direct thrombin inhibitors (Prodaxa), low molecular weight heparins (Fraxiparine, Clexane) can be used to prevent thromboembolism.

High levels of cholesterol in the blood lead to the risk of developing atherosclerotic plaques. Due to blockage of blood vessels by atherosclerotic plaques, myocardial infarction, ischemic stroke or gangrene of the extremities develops.

The most famous analogues and substitutes of Roxers

Direct analogues and substitutes of Roxers are called “synonyms” or “generics” - drugs based on the same active substance that are interchangeable in their action. They differ from the original development in manufacturing technology, commercial name and the number of additional components.

Since the effectiveness of such drugs, as a rule, is not inferior to the original, the patient has the right to choose an acceptable generic, focusing on allergic intolerance, budget or other personal preferences. The main thing is to follow the dosage and dosage regimen prescribed by the doctor.

Mertenil

Mertenil is one of the best analogues of Roxera. It is distinguished by the highest degree of purification of the active ingredient, which ensures its good tolerability even with long-term use. In this regard, Mertenil is often used to treat elderly and minor patients.

Features of the composition: it is identical to the original in everything, except for the dye.

Company, country of origin: Gedeon Richter, Hungary.

Approximate cost: from 487 rub./30 pcs. 5 mg up to RUB 1,436/30 pcs. 40 mg.

Rosuvastatin-SZ

Rosuvastatin-C3 (Rosuvastatin-SZ) is a cheaper analogue of domestically produced Roxera. It has the same amount of rosuvastatin as the original, but differs slightly in the volume of auxiliary ingredients, which makes it a less balanced and fast-acting medicine.

Features of the composition: contains soy lecithin and 3 types of aluminum varnish.

Company, country of origin: FC North Star 3AO, Russia

Approximate cost: from 162 rub./30 pcs. 5 mg up to RUR 679/30 pcs. 40 mg.

Crestor

Crestor is an original drug based on rosuvastatin, which costs much more than its analogues. It is minimally metabolized in the liver (less than 10%), which greatly reduces the likelihood of adverse reactions in the body - this is confirmed by numerous positive reviews from patients.

Features of the composition: originally patented medicinal formula.

Company, country of origin: Astra Zeneca, England.

Approximate cost: from 1685 to 5162 rubles.

Rosart

Rosart is the most versatile replacement for Roxera. The medicine very rarely causes a negative reaction from the body, because both the active substance and the auxiliary components undergo thorough purification. That is, the analogue has all the advantages of the original and at the same time costs much less than it.

Features of the composition: the recipe corresponds to the original, except for the dye.

Company, country of origin: Actavis Group, Iceland.

Approximate cost: from 422 rub./30 pcs. 5 mg up to RUB 1,318/30 pcs. 40 mg.

Suwardio

Suvardio is another Slovenian drug. In Russia, it is presented in a limited range - only 10 and 20 mg, which makes it an unsuitable option for starting therapy, since, in order to avoid incorrect dosing, rosuvastatin tablets are not recommended to be divided into parts.

Features of the composition: dry corn starch is used as a base.

Company, country of origin: Sandoz, Slovenia.

Approximate cost: from 382 to 649 rubles.

Main differences, effectiveness and safety

These medications do not have any special differences and are prescribed with the same dosage and can be substitutes for each other. Therefore, to the question of how Liprimar differs from Atorvastatin, we can answer that both medications belong to the same generation and have atorvastatin as the main component of the drug. The only difference is the price of the drugs. Liprimar costs 7-8 times more than Atorvastatin, because Liprimar is considered the original drug of this generation of drugs and is produced in the USA.

Both medications have an almost identical composition and the same active ingredient, but Liprimar is more effective as an original medication. The Russian analogue Atorvastatin is slightly inferior in this regard and has more negative effects on the body. In addition, Liprimar is used in pediatrics.

Statins have many side effects, but proper adherence to all doctor’s recommendations reduces the risk of developing negative reactions of the body to medications. The main side effects of drugs based on atorvastatin: